TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07520565: A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.

Sponsor: Biocells (Beijing) Biotech Co.,Ltd · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 1112 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07520565 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07520565 Rescue Dossier →